With Oyster Point Pharma announcing results from the Phase IIb PEARL study, company president and CEO Jeffrey Nau, PhD, talks with OIS Podcast about what the findings mean for OC-02, a nicotinic acetylcholine receptor agonist the company is developing to treat the signs and symptoms of dry eye disease. The study met both primary endpoints by showing a statistically significant improvement in signs and symptoms compared with control. Top-line data from the study will be presented this weekend at the American-European Congress of Ophthalmic Surgery Summer Symposium in Deer Valley, UT. OC-02 is delivered as a nasal spray and stimulates the trigeminal parasympathetic pathway to activate the glands responsible for producing the eye’s natural tear film.
Meet Our Host
Joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.